Experimental Eye Treatment CSB-001 Shows Promising Vision Gains in Clinical Study
CSB-001 eye treatment gave 41% of treated eyes 15+ letters in an open-label limbal stem cell deficiency study. The data, the limits and what comes next.
Experimental Eye Treatment CSB-001 Shows Promising Vision Gains in Clinical Study
CSB-001 eye treatment gave 41% of treated eyes 15+ letters in an open-label limbal stem cell deficiency study. The data, the limits and what comes next.
Sahajanand Medical Technologies IPO: ₹327–₹344 Price Band Announced for ₹475 Crore Issue
Sahajanand Medical Technologies IPO opens 15 October at ₹327-344, a ₹475 crore offer for sale. Dates, lot size, financials, valuation and risks.
FDA Grants Fast Track Status to New Biliary Tract Cancer Immunotherapy, Opamtistomig
Opamtistomig FDA Fast Track granted for first-line biliary tract cancer, nine days after filing. What it means, the data so far and what is unknown.
Mystery Surrounds Young Worker’s Death at Russia Lab Studying Severe Diseases
Russia lab worker death: a young employee of a plague institute died of pneumonia. WHO sees no spread, 5,500 tests found no pathogen, cause unknown.
Alumis Reports 48-Week Phase 3 Data for Envudeucitinib in Plaque Psoriasis
Envudeucitinib plaque psoriasis: Alumis reports 54% complete skin clearance at 48 weeks in Phase 3 ONWARD3 and plans an NDA in Q4 2026.
New York Governor to Seek Federal Help on Measles Outbreak
The New York measles outbreak has 108 cases as Governor Hochul seeks HHS and CDC help after Kennedy offered support. What is confirmed so far.
Kennedy Launches New Push on Vaccine Injuries: What HHS Revealed
The vaccine injury initiative from HHS Secretary Kennedy adds an NIH clinic, VAERS changes and a CMS proposal. See what is known and what is not.
City Therapeutics Eyes Valuation of Up to $956.3 Million in US IPO
The City Therapeutics IPO targets a valuation of up to about $956 million at $17 to $19 a share. Terms, RNAi pipeline, financials and risks.
Teva Wins FDA Approval for Monthly Schizophrenia Injection Weltruza
Weltruza FDA approval gives Teva a once-monthly subcutaneous olanzapine injection for adults with schizophrenia. Doses, trial data, safety, launch.
